Indexed keywords
CD20 ANTIBODY;
CORTICOSTEROID;
RITUXIMAB;
ADULT;
ARTICLE;
CASE REPORT;
CATARACT;
CORTICOSTEROID THERAPY;
FEMALE;
FOLLOW UP;
HUMAN;
IMMUNOSUPPRESSIVE TREATMENT;
IMMUNOTHERAPY;
IRIDOCYCLITIS;
LOW DRUG DOSE;
OPHTHALMOSCOPE;
PATIENT SELECTION;
PRIORITY JOURNAL;
RETINA MACULA CYSTOID EDEMA;
VISUAL ACUITY;
ANTIBODIES, MONOCLONAL;
ANTIGENS, CD20;
CHRONIC DISEASE;
FEMALE;
FLUORESCEIN ANGIOGRAPHY;
FOLLOW-UP STUDIES;
FUNDUS OCULI;
HUMANS;
IMMUNOLOGIC FACTORS;
INFUSIONS, INTRAVENOUS;
MIDDLE AGED;
OPHTHALMOSCOPY;
TOMOGRAPHY, OPTICAL COHERENCE;
UVEITIS, ANTERIOR;
1
2942537697
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards JC, Szczepanski L, Szechinski J, et al: Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004;350:2572-2581.
(2004)
N Engl J Med , vol.350
, pp. 2572-2581
Edwards, J.C.1
Szczepanski, L.2
Szechinski, J.3
2
0642275751
New options in treatment of therapy refractory vasculitis
Lamprecht P: New options in treatment of therapy refractory vasculitis. Z Rheumatol 2003;62:114-115.
(2003)
Z Rheumatol , vol.62
, pp. 114-115
Lamprecht, P.1
3
0034940321
Treatment of refractory autoimmune haemolytic anaemia with anti-CD20 (rituximab)
Ahrens N, Kingreen D, Seltsam A, et al: Treatment of refractory autoimmune haemolytic anaemia with anti-CD20 (rituximab). Br J Haematol 2001;114:244-245.
(2001)
Br J Haematol , vol.114
, pp. 244-245
Ahrens, N.1
Kingreen, D.2
Seltsam, A.3
4
3142566462
Rituximab therapy for life-threatening immune hemolytic anemia in a liver transplant recipient: A case report
Akyildiz M, Karasu Z, Cagirgan S, et al: Rituximab therapy for life-threatening immune hemolytic anemia in a liver transplant recipient: a case report. Transplant Proc 2004;36:1492-1493.
(2004)
Transplant Proc , vol.36
, pp. 1492-1493
Akyildiz, M.1
Karasu, Z.2
Cagirgan, S.3
5
0036785195
Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab)
Arzoo K, Sadeghi S, Liebman HA: Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab). Ann Rheum Dis 2002;61:922-924.
(2002)
Ann Rheum Dis , vol.61
, pp. 922-924
Arzoo, K.1
Sadeghi, S.2
Liebman, H.A.3
6
0037819344
An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab
Boye J, Elter T, Engert A: An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol 2003;14:520-535.
(2003)
Ann Oncol , vol.14
, pp. 520-535
Boye, J.1
Elter, T.2
Engert, A.3
7
22544433562
Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus
Arin MJ, Engert A, Krieg T, et al: Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol 2005;153:620-625.
(2005)
Br J Dermatol , vol.153
, pp. 620-625
Arin, M.J.1
Engert, A.2
Krieg, T.3
8
84856488806
Crossroads of B cell activation in autoimmunity: Rationale of targeting B cells
Dorner T: Crossroads of B cell activation in autoimmunity: rationale of targeting B cells. J Rheumatol Suppl 2006;77:3-11.
(2006)
J Rheumatol Suppl , vol.77
, pp. 3-11
Dorner, T.1
9
29344460633
The therapeutic potential of anti-CD20 'what do B-cells do?' Clin
Eisenberg R, Looney RJ: The therapeutic potential of anti-CD20 'what do B-cells do?' Clin Immunol 2005;117:207-213.
(2005)
Immunol , vol.117
, pp. 207-213
Eisenberg, R.1
Looney, R.J.2
